Test whether under PAC1 antagonist (PACAP(6-38)) or Adcyap1r1 / PAC1 LOF that abolishes PAC1-class neuroprotection / cognition attribution, PACAP-38 (or maxadilan) still retains neuroprotective or cognitive phenotype

PACAP-38 (and maxadilan) is framed as supporting neuroprotection and cognition through PAC1-class attribution, yet that framing is often assumed to exhaust the phenotype. This discussion asks whether residual PACAP-38 (or maxadilan) neuroprotection or cognition under a PAC1 antagonist (PACAP(6-38)) or Adcyap1r1 / PAC1 LOF that abolishes PAC1-class neuroprotection / cognition attribution still requires a path beyond PAC1-class attribution.

Claim

On a matched rodent cognition / neuroprotection panel (Reglodi/Sacchetti/Otto/Gourlet-class, or Telegdy/Manavalan-class style matched rodent NP/cognition panel) ± PACAP-38 (or maxadilan) ± PAC1 antagonist (PACAP(6-38)) or Adcyap1r1 / PAC1 genetic LOF titrated so the block abolishes PAC1-class neuroprotection / cognition attribution, plus neuroprotective or cognitive endpoint: under that PAC1-abolish condition, residual PACAP-38 (or maxadilan) neuroprotective / cognitive phenotype remains ≥50% of the PACAP-38/maxadilan without-PAC1-abolish arm on the same panel (named comparator = PACAP-38/maxadilan without-PAC1-abolish arm under matched panel) — assumption-kill / pac1-insufficiency.

Why it matters

Reglodi / Sacchetti map PACAP-38 delayed MCAO neuroprotection and low-dose passive-avoidance memory phenotypes; Otto maps PAC1 as necessary for mossy-fiber LTP / associative learning; Gourlet maps PACAP(6-38)-class fragments as type-I (PAC1) vs type-II receptor-discrimination tools. P26 asks whether residual PACAP-38 (or maxadilan) neuroprotection / cognition under a PAC1 antagonist or Adcyap1r1 / PAC1 LOF that abolishes PAC1-class attribution still requires a path beyond PAC1-class attribution — pac1-insufficiency assumption-kill. Distinct from P15 (BPC residual-FBXO22), P16 (LKKTETQ-Cc), P17 (MOTS-c/folate), P18 (SS-31/ROS-scavenger), P19 (ARA290/IRR), P20 (Semax/TrkB; PACAP≠Semax; PAC1≠TrkB), P21 (Selank/GABA; PACAP≠Selank; PAC1≠GABA), P22 (Dihexa/c-Met; PACAP≠Dihexa; PAC1≠c-Met), P23 (oxytocin/OXTR; PACAP≠oxytocin; PAC1≠OXTR), P24 (Exendin-4/GLP1R; PACAP≠Exendin-4; PAC1≠GLP1R), and P25 (ghrelin/GHSR; PACAP≠ghrelin; PAC1≠GHSR); NOT FOXO4×LOF; skip-list unused; orthosteric_drift=false; VPAC type-II adjacent ≠ PAC1 claim core. Soft-claims: discussion — matched residual-under-PAC1-abolish H2H UNKNOWN; PRIOR_ART PARTIAL (necessity AGAINST residual for PACAP-38 cognition / in-vitro NP); soft-complete empty ≠ novelty / ≠ failure; P1–P25 ≠ proof.

Mechanism sketch

pac1-insufficiency assumption-kill: Reglodi shows delayed systemic PACAP38 MCAO neuroprotection LITERATURE (no PACAP(6-38) / Adcyap1r1 LOF residual arm); Sacchetti shows i.c.v. PACAP-38 low-dose passive-avoidance memory phenotype LITERATURE (no residual arm); Otto shows PAC1-deficient mice impaired mossy-fiber LTP and contextual fear / associative learning LITERATURE — necessity AGAINST residual for PAC1-class cognition (not exogenous PACAP-38 residual under PAC1 abolish); Gourlet shows PACAP fragments discriminate type-I (PAC1) vs type-II receptors with PACAP-(6-38)-class tools LITERATURE (tool prior, not CNS residual H2H) — none score residual PACAP-38/maxadilan under a PAC1 antagonist / Adcyap1r1 LOF that abolishes PAC1-class neuroprotection / cognition attribution on the same panel. Promoted Telegdy (PMID 10960604; out of public prior_art ≤4) shows PACAP 6-38 completely blocked PACAP-38 passive-avoidance consolidation — stronger necessity H2H AGAINST residual for PACAP-38 cognition; not residual-positive. Promoted Manavalan (PMID 28342135; out of public prior_art ≤4) shows PACAP EtOH/nicotine NP in SH-SY5Y blocked by PACAP 6-38 — necessity H2H AGAINST residual for that in-vitro NP panel; not residual-positive. Adjacent Adamik/Schmidt/Telegdy antagonist-impairs-memory tool priors (15680470; 25490058; 33705861; 25543171) and 42296776 cardiac PACAP6-38 block NON-MATCH CNS panel — not public prior_art anchors. VPAC type-II adjacent (Q_VPAC) honesty ≠ PAC1 residual claim. PAC1-class neuroprotection / cognition framing is the class PRIOR under kill — PRIOR necessity / phenotype ≠ matched residual-positive H2H under PAC1-abolish. Do not invent residual; do not treat necessity as residual-positive; do not conflate VPAC1/2 residual with PAC1 claim. P26 scores residual neuroprotection / cognition under PAC1 antagonist (PACAP(6-38)) or Adcyap1r1 / PAC1 LOF that first abolishes PAC1-class attribution, on the same panel ± PACAP-38 (or maxadilan) ± PAC1-abolish (prefer cell / slice / block-QC with PACAP(6-38) or Adcyap1r1 ablation before new animal Reglodi/Sacchetti/Otto/Gourlet-class cognition / neuroprotection panels; still name the in vivo panel as primary kill path). Explicitly NOT FOXO4×LOF (SERIES_FROZEN); NOT BPC-157 / FBXO22 / VEGFR2 / OpenLabs skip-list 8e5ba06c or 7db12286 orthosteric dialect; NOT P15 residual-FBXO22; NOT P16 LKKTETQ under G-actin Cc; NOT P17 MOTS-c residual under folate repletion; NOT P18 SS-31 residual under matched ROS-scavenger; NOT P19 ARA290 residual under hematopoietic-matched EPO; NOT P20 Semax residual under TrkB antagonist / BDNF neutralize (PACAP ≠ Semax; PAC1 ≠ TrkB); NOT P21 Selank residual under GABA-A/BDZ match (PACAP ≠ Selank; PAC1 ≠ GABA); NOT P22 Dihexa residual under HGF/c-Met block (PACAP ≠ Dihexa; PAC1 ≠ c-Met); NOT P23 oxytocin residual under OXTR antagonist / Oxtr LOF (PACAP ≠ oxytocin; PAC1 ≠ OXTR); NOT P24 Exendin-4 residual under GLP1R antagonist / Glp1r LOF (PACAP ≠ Exendin-4; PAC1 ≠ GLP1R); NOT P25 ghrelin residual under GHSR1a antagonist / Ghsr LOF (PACAP ≠ ghrelin; PAC1 ≠ GHSR). Soft-complete empty ≠ novelty / ≠ failure.

Prior art

• PMID 10835464 / DOI 10.1161/01.str.31.6.1411 — Reglodi: delayed systemic PACAP38 neuroprotective in transient MCAO rat (infarct reduced when started 4 h after MCAO) — PACAP38 MCAO neuroprotection phenotype PRIOR (no PACAP(6-38) / Adcyap1r1 LOF residual arm).
• PMID 11525248 / DOI 10.1006/nlme.2001.4014 — Sacchetti: i.c.v. PACAP-38 at very low dosages improves passive-avoidance memory (inverted-U) — cognition phenotype PRIOR (no PACAP(6-38) / PAC1 LOF residual arm).
• PMID 11466423 / DOI 10.1523/JNEUROSCI.21-15-05520.2001 / PMC6762677 — Otto: PAC1-deficient mice (complete + forebrain-specific) impaired mossy-fiber LTP and contextual fear conditioning (associative learning); cued fear intact — PAC1 necessity for PAC1-class associative learning / mossy-fiber LTP AGAINST residual for that cognition panel; not exogenous PACAP-38 residual under PAC1 abolish.
• PMID 8666028 / DOI 10.1016/0014-2999(95)00467-5 — Gourlet: PACAP fragments discriminate type-I (PAC1) vs type-II (VIP1/VIP2) recombinant receptors; PACAP-(6-38)-class tools discriminate subtypes — receptor-discrimination TOOL PRIOR (not CNS residual H2H).

Baseline claimed

Under PAC1 antagonist (PACAP(6-38)) or Adcyap1r1 / PAC1 genetic LOF that abolishes PAC1-class neuroprotection / cognition attribution, PACAP-38 (or maxadilan) still retains neuroprotective or cognitive phenotype on the same panel — or Reglodi/Sacchetti/Otto/Gourlet phenotype / necessity / tool / Telegdy PACAP 6-38 block / Manavalan PACAP 6-38 block / Adamik-Schmidt tool / 42296776 cardiac / VPAC type-II / P15 residual-FBXO22 / P16 LKKTETQ-Cc / P17 MOTS-c/folate / P18 SS-31/ROS / P19 ARA290/IRR / P20 Semax/TrkB / P21 Selank/GABA / P22 Dihexa/c-Met / P23 oxytocin/OXTR / P24 Exendin/GLP1R / P25 ghrelin/GHSR / P1–P25 already settle residual-under-PAC1-abolish.

Baseline measured

Reglodi PACAP38 delayed MCAO NP LITERATURE (PMID 10835464; phenotype without PACAP(6-38) / Adcyap1r1 LOF residual arm). Sacchetti i.c.v. PACAP-38 low-dose passive-avoidance memory LITERATURE (PMID 11525248; phenotype without residual arm). Otto PAC1-deficient mice impaired mossy-fiber LTP / associative learning LITERATURE (PMID 11466423; necessity AGAINST residual for PAC1-class cognition; not exogenous PACAP residual under PAC1 abolish). Gourlet PACAP(6-38)-class type-I vs type-II discrimination LITERATURE (PMID 8666028; tool ≠ CNS residual H2H). Promoted Telegdy PACAP 6-38 completely blocked PACAP-38 passive-avoidance consolidation LITERATURE (PMID 10960604; out of public prior_art ≤4; necessity H2H AGAINST residual for PACAP-38 cognition). Promoted Manavalan PACAP EtOH/nicotine NP in SH-SY5Y blocked by PACAP 6-38 LITERATURE (PMID 28342135; out of public prior_art ≤4; necessity H2H AGAINST residual for that in-vitro NP). Adjacent Adamik/Schmidt/Telegdy antagonist-impairs-memory tool priors LITERATURE (PMID 15680470; 25490058; 33705861; 25543171; not public prior_art). 42296776 cardiac PACAP6-38 block NON-MATCH CNS panel LITERATURE. VPAC type-II adjacent ≠ PAC1 residual claim. Matched residual-positive PACAP-38/maxadilan neuroprotection / cognition under PAC1 antagonist / Adcyap1r1 LOF that abolishes PAC1-class attribution on same panel UNKNOWN (soft-complete Q_resid NON-MATCH / Q_resid_tight NON-MATCH / Q_block necessity-leaning / Q_necess_h2h necessity AGAINST / Q_resid_persist NON-MATCH residual-positive cognition/NP / Q_maxadilan_resid NON-MATCH / Q_VPAC type-II adjacent ≠ PAC1 / Q_P25_tight NON-MATCH PACAP≠ghrelin PAC1≠GHSR / Q_P24 NON-MATCH PACAP≠Exendin-4 PAC1≠GLP1R / Q_P23 NON-MATCH / Q_P22 NON-MATCH / Q_P21 NON-MATCH / Q_P20 NON-MATCH / FOXO4∩PACAP NON-MATCH / BPC∩PACAP=0 / P15–P19 drift empty). Residual ≥50% of PACAP-38/maxadilan without-PAC1-abolish arm under PAC1-abolish condition PREDICTION (author-chosen; not invented observed effect). P15 ≠ P26; P16 ≠ P26; P17 ≠ P26; P18 ≠ P26; P19 ≠ P26; P20 ≠ P26; P21 ≠ P26; P22 ≠ P26; P23 ≠ P26; P24 ≠ P26; P25 ≠ P26; P1–P25 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT FOXO4×LOF. Do not invent residual; do not treat necessity as residual-positive; do not conflate VPAC1/2 with PAC1 claim.

Actionable limitations

1. Do not treat P1–P25 as proving P26 — Reglodi/Sacchetti/Otto/Gourlet phenotype / necessity / tool priors are not a residual-under-PAC1-abolish H2H for PACAP-38/maxadilan; Telegdy / Manavalan PACAP 6-38 blocks lean AGAINST residual; soft-complete empty ≠ demonstrated residual phenotype; do not invent residual when UNKNOWN; do not treat necessity as residual-positive; do not conflate VPAC type-II with PAC1 claim.
2. Skip-list / series distinctness (critical) — do not freeze or collapse to OpenLabs 8e5ba06c / 7db12286 BPC orthosteric dialect, P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS-scavenger, P19 ARA290/IRR, P20 Semax/TrkB (PACAP≠Semax; PAC1≠TrkB), P21 Selank/GABA (PACAP≠Selank; PAC1≠GABA), P22 Dihexa/c-Met (PACAP≠Dihexa; PAC1≠c-Met), P23 oxytocin/OXTR (PACAP≠oxytocin; PAC1≠OXTR), P24 Exendin/GLP1R (PACAP≠Exendin-4; PAC1≠GLP1R), or P25 ghrelin/GHSR (PACAP≠ghrelin; PAC1≠GHSR); orthosteric_drift=false; REJECT if claim drifts to BPC/FBXO22/VEGFR2 or LKKTETQ/Tβ4 sequestration or MOTS-c/folate or SS-31/cardiolipin/MitoTEMPO or ARA290/IRR or Semax/TrkB/BDNF or Selank/GABA/BDZ or Dihexa/HGF/c-Met or oxytocin/OXTR or Exendin/GLP1R or ghrelin/GHSR; NOT FOXO4×LOF (SERIES_FROZEN).
3. Reglodi/Sacchetti lack a PACAP-38/maxadilan residual arm under PAC1-abolish on a cognition/NP panel; abolish-fail (PAC1-class attribution not abolished) / agonist-alone-null / underpowered strata / assay-mismatch leave the test inconclusive rather than refuted; do not misread Otto PAC1 LOF necessity or Telegdy/Manavalan PACAP 6-38 block as residual-positive; prefer cell/slice/block-QC before new animal; no dosing; reviews ≠ experimental anchors; VPAC≠PAC1.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: peptides, nootropics risk_class: research-discussion

Prediction variables

Ablate

• remove matched cognition / neuroprotection panel ± PACAP-38 (or maxadilan) ± PAC1 antagonist or Adcyap1r1 / PAC1 LOF under PAC1-abolish that first abolishes PAC1-class neuroprotection / cognition attribution, then scores residual PACAP-38/maxadilan neuroprotection / cognition: Without the PAC1-abolish × residual H2H, separate Reglodi/Sacchetti phenotype LITERATURE, Otto necessity LITERATURE, and Gourlet tool LITERATURE cannot show pac1-insufficiency of residual PACAP-38/maxadilan under PAC1-abolish.
• remove PAC1-abolish gate plus PACAP-38/maxadilan without-PAC1-abolish arm as the named residual comparator (vs Reglodi/Sacchetti/Otto/Gourlet phenotype-alone / necessity-alone / tool-alone / Telegdy/Manavalan PACAP 6-38 block-alone): Without the PAC1-abolish gate and PACAP-38/maxadilan without-abolish comparator under the same block condition, the card collapses into Reglodi/Sacchetti/Otto/Gourlet phenotype / necessity / tool prior or generic PAC1-class framing and loses pac1-insufficiency contrast.
• remove P15≠P26 + P16≠P26 + P17≠P26 + P18≠P26 + P19≠P26 + P20≠P26 + P21≠P26 + P22≠P26 + P23≠P26 + P24≠P26 + P25≠P26 + P1–P25≠proof + soft-complete-empty≠novelty + skip-list-distinct + NOT-FOXO4×LOF + do-not-invent-residual-when-UNKNOWN + do-not-treat-necessity-as-residual-positive + VPAC≠PAC1 discipline: Treating P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS, P19 ARA290/IRR, P20 Semax/TrkB, P21 Selank/GABA, P22 Dihexa/c-Met, P23 oxytocin/OXTR, P24 Exendin/GLP1R, P25 ghrelin/GHSR, empty PubMed, Reglodi/Sacchetti/Otto/Gourlet alone as residual-positive, Telegdy/Manavalan necessity as residual-positive, VPAC type-II as PAC1 claim core, or FOXO4/BPC framing as already deciding residual-under-PAC1-abolish would invent an H2H result left UNKNOWN.

Refute if

On the pre-registered matched rodent cognition / neuroprotection panel (Reglodi/Sacchetti/Otto/Gourlet-class, or Telegdy/Manavalan-class style) ± PACAP-38 (or maxadilan) ± PAC1 antagonist (PACAP(6-38)) or Adcyap1r1 / PAC1 genetic LOF where PAC1-abolish abolishes PAC1-class neuroprotection / cognition attribution, residual PACAP-38 (or maxadilan) neuroprotective / cognitive phenotype is <50% of the PACAP-38/maxadilan without-PAC1-abolish arm under that same condition — so PAC1-class-attribution framing survives and pac1-insufficiency residual fails — when abolish-fail, agonist-alone-null, underpowered strata, or assay-mismatch artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Lock one matched rodent cognition / neuroprotection panel (Reglodi/Sacchetti/Otto/Gourlet-class, or Telegdy/Manavalan-class style) ± PACAP-38 (or maxadilan) ± PAC1 antagonist (PACAP(6-38)) or Adcyap1r1 / PAC1 genetic LOF with block QC that abolishes PAC1-class neuroprotection / cognition attribution, neuroprotective / cognitive readout, and ≥50%-of-PACAP-38/maxadilan-without-PAC1-abolish residual gate before claiming residual under PAC1 abolish; prefer cell / slice / block-QC with PACAP(6-38) or Adcyap1r1 ablation before new animal cognition / neuroprotection panels (in vivo panel remains primary kill path); do not treat P15 or P16 or P17 or P18 or P19 or P20 or P21 or P22 or P23 or P24 or P25 or P1–P25 as proof; do not collapse to BPC/FBXO22/VEGFR2 skip-list orthosteric dialect or LKKTETQ/Tβ4 sequestration or MOTS-c/folate or SS-31/cardiolipin/MitoTEMPO or ARA290/IRR or Semax/TrkB/BDNF or Selank/GABA/BDZ or Dihexa/HGF/c-Met or oxytocin/OXTR or Exendin/GLP1R or ghrelin/GHSR; do not invent residual when UNKNOWN; do not treat necessity as residual-positive; do not conflate VPAC1/2 with PAC1 claim; no dosing; NOT FOXO4×LOF.

Cheap IP

kill_cost_tier=1 · time_to_refute=4w · ip_class=pac1-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=Reglodi PACAP38 delayed MCAO NP phenotype (no residual arm); Sacchetti PACAP-38 low-dose memory phenotype (no residual arm); Otto PAC1 LOF mossy-fiber LTP / associative learning necessity AGAINST residual for PAC1-class cognition; Gourlet PACAP(6-38)-class type-I vs type-II TOOL; Telegdy PACAP 6-38 completely blocked PACAP-38 consolidation (promoted necessity; out of public prior_art ≤4); Manavalan PACAP EtOH/nicotine NP blocked by PACAP 6-38 (promoted necessity; out of public prior_art ≤4); Adamik/Schmidt/Telegdy antagonist-impairs-memory adjacent tool; 42296776 cardiac NON-MATCH CNS; P15 (BPC residual-FBXO22 ≠ PACAP×PAC1 residual; P15 ≠ P26); P16 (LKKTETQ-Cc ≠ PACAP×PAC1; P16 ≠ P26); P17 (MOTS-c/folate ≠ PACAP×PAC1; P17 ≠ P26); P18 (SS-31/ROS ≠ PACAP×PAC1; P18 ≠ P26); P19 (ARA290/IRR ≠ PACAP×PAC1; P19 ≠ P26); P20 (Semax/TrkB ≠ PACAP×PAC1; PACAP≠Semax; PAC1≠TrkB; P20 ≠ P26); P21 (Selank/GABA ≠ PACAP×PAC1; PACAP≠Selank; PAC1≠GABA; P21 ≠ P26); P22 (Dihexa/c-Met ≠ PACAP×PAC1; PACAP≠Dihexa; PAC1≠c-Met; P22 ≠ P26); P23 (oxytocin/OXTR ≠ PACAP×PAC1; PACAP≠oxytocin; PAC1≠OXTR; P23 ≠ P26); P24 (Exendin/GLP1R ≠ PACAP×PAC1; PACAP≠Exendin-4; PAC1≠GLP1R; P24 ≠ P26); P25 (ghrelin/GHSR ≠ PACAP×PAC1; PACAP≠ghrelin; PAC1≠GHSR; P25 ≠ P26); P1–P25 ≠ proof

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: peptides, nootropics risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/P26.card.md card_sha256: 1cb2a480583f9964c16b2d06d6f202c910c95f3fba420b1edc49d536e6c1ae0b

Mol Labs public report: PENDING dual-publish